EU Court upholds EU parliament's decision to recover funds from Jean-Marie Le Pen
BRUSSELS (Reuters) -The EU's General Court upheld on Wednesday a European Parliament (EP) decision requiring the estate of late French far-right politician Jean-Marie Le Pen to repay 303,200 euros ($352,380) for wrongly claimed expenses during his time as a member of the parliament.
After Le Pen died in January 2025 aged 96, his daughters Yann and Marie-Caroline and granddaughter Marion continued the legal challenge he had begun in January 2024.
Le Pen, who founded the National Front political party that was later renamed as the National Rally (NR) and was a member of the EP from 1984 to 2019, had contested the parliament's demand for repayment, arguing it violated legal certainty, legitimate expectations, and his right to a fair trial. The funds had been charged as official MEP expenses.
The Court rejected the claims, affirming that the European Parliament followed due process: Le Pen was properly notified, allowed to respond, and failed to justify the expenses. It also ruled that fair trial rights apply only to judicial, not administrative, proceedings.
The National Rally party did not immediately reply to a request for comment.
($1 = 0.8604 euros)
(Reporting by Charlotte Van CampenhoutEditing by Frances Kerry)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysia Sun
7 hours ago
- Malaysia Sun
State Department accuses EU of Orwellian censorship
The US government agency says the blocs online content-moderation policies violate free speech The EU's online content regulations are an affront to free speech, the US State Department has said in response to France's praise for the Digital Services Act (DSA). The State Department echoed earlier criticism from US Vice President J.D. Vance, who accused EU member states of attempting to quash dissenting voices and stigmatize popular right-wing parties such as Alternative for Germany (AfD). "In Europe, thousands are being convicted for the crime of criticizing their own governments. This Orwellian message won't fool the United States. Censorship is not freedom," the State Department wrote on X on Tuesday. "All the DSA protects is European leaders from their own people." Earlier this month, France's mission to the UN promoted the DSA on X, stating, "In Europe, one is free to speak, not free to spread illegal content." Passed in 2022, the DSA mandates that online platforms remove "illegal and harmful" content and combat "the spread of disinformation," according to the European Commission. Critics in both the US and Europe have likened the regulations to the creation of a bloc-wide "ministry of truth." Earlier this year, prosecutors in Paris launched an investigation into Elon Musk's platform X, on suspicion that it was being used to meddle in French politics and spread hateful messages. The company dismissed the probe as "politically motivated." In 2024, French authorities detained Russian-born tech entrepreneur Pavel Durov on charges that he had allowed his Telegram messaging app to be used for criminal activities. Durov, who was later released on bail, denied any wrongdoing and accused France of waging "a crusade" against free speech. He also claimed that French intelligence officials attempted to pressure him into censoring content during Romania's 2024 presidential election. France's foreign intelligence agency, the DGSE, confirmed that it had "reminded" Durov of his responsibility to police content, but denied allegations of election interference. (
The Sun
7 hours ago
- The Sun
Macron and Merz to discuss NATO, US-EU trade in Berlin talks
BERLIN: French President Emmanuel Macron will hold talks with German Chancellor Friedrich Merz in Berlin on Wednesday, focusing on NATO security, the US-EU trade dispute, and other pressing issues. The meeting comes as both leaders seek to strengthen Franco-German ties amid growing transatlantic tensions under US President Donald Trump. 'The most important message is: the Franco-German couple is back at work,' the French presidency said ahead of Macron's planned dinner with Merz. The two leaders aim to reinforce cooperation at the heart of the European Union, particularly as Trump's policies continue to strain relations between the US and Europe. Paris and Berlin have been key players in supporting Ukraine against Russian aggression and bolstering NATO's European defence capabilities. However, while France has hinted at deploying peacekeeping troops to monitor a potential ceasefire in Ukraine, Germany has not yet committed to such a move. Trade tensions with the US will also dominate discussions. Trump has threatened to impose 30% tariffs on EU goods if no agreement is reached by August 1. 'In the tariff dispute with the USA, we are now approaching the decisive phase,' Merz said Tuesday, calling for 'a fair and reliable agreement with low tariff rates' to stabilise transatlantic trade. Bilateral disagreements remain, particularly over a joint combat aircraft project involving Spain. Merz has resisted France taking a dominant role but remains optimistic about reaching a consensus. Meanwhile, Dassault CEO Eric Trappier has raised doubts about the project's feasibility, citing challenges in a three-nation leadership structure. Energy policy is another sticking point. France advocates for nuclear power as a climate-friendly solution, while Germany is phasing it out in favour of renewables. Macron seeks German support for EU-level recognition of nuclear energy, a stance Merz's centre-right coalition may be more open to than the previous government. The leaders will also address the long-delayed EU-Mercosur trade deal, with France cautious about its impact on agriculture. Sources suggest a compromise may include safeguards for the farming sector. Merz will host Macron at Villa Borsig, with a schedule including a jazz performance and a working dinner. - AFP
The Star
14 hours ago
- The Star
AstraZeneca vows to spend US$50bil on US manufacturing boost
LONDON: AstraZeneca Plc plans to invest US$50bil in the United States before 2030, becoming the latest European pharma company to ratchet up spending in the country ahead of potential tariffs on imported medicines. The investment will go towards manufacturing as well as research and development, Astra said in a statement. It includes US$4bil for a new facility in Virginia that will make drugs for chronic diseases, Kevin Hassett, director of the US National Economic Council, said on Monday at an event in Washington. 'With the completion of this investment, substantially all of AstraZeneca's pharmaceuticals sold in the United States will be produced in the United States,' he said. Astra will also manufacture its experimental weight-loss pill at the facility in Virginia, following an earlier pledge from rival Eli Lilly & Co, which is also planning to make its obesity pill in the United States. The announcement comes as European drug companies rush to highlight their US investments with the aim of mitigating the impact of tariffs from President Donald Trump. Astra already announced plans in November, a week after Trump's election, to invest US$3.5bil in the United States by the end of 2026, noting at the time that it employs nearly 18,000 people in the country. The company said the latest investment announcement is in addition to that earlier amount. Since Trump's election, European competitors have touted ever-larger spending plans. Switzerland's Novartis AG in April announced plans for US$23bil in US-based infrastructure spending, while cross-town rival Roche Holding AG said it would invest US$50bil. In May, French drugmaker Sanofi announced intent to invest at least US$20bil in the United States by 2030. Pascal Soriot, who's been chief executive officer of Astra since 2012, had urged tariff restraint from US policymakers. This spring, he recommended that US officials exempt medicines from tariffs, arguing that tax incentives are a better way to attract investment in drug development and manufacturing. On Monday, Soriot said he understands the need for countries to have medicines manufactured domestically. 'It's a question of national security,' he said. 'This is a vision that the president and his administration have put out there, and a vision that we totally understand, totally support, and the tariffs are accelerating a movement that we would have made in any case.' Trump has proposed various timelines for tariffs on pharmaceuticals, most recently floating duties that would start as soon as Aug 1. The president said he expects to give companies a year to bring manufacturing to the United States before imposing tariffs as high as 200%. Meanwhile, Soriot has raised concerns in the United Kingdom about his company's commitment to its home country. He has long complained about the United Kingdom's regulatory environment, which he says is a threat to hold the nation back from staying competitive with the United States and China. In January, Astra abandoned plans for a £450mil vaccine manufacturing plant in Liverpool. The company operates 17 manufacturing sites in 12 US states. Earlier this month, British paper The Times reported that Soriot is considering moving the company's stock listing to the United States. — Bloomberg
